Table 3

Therapeutic response and low disease activity among ADAb-negative and ADAb-positive patients, at study beginning

Patients ADAb + (n=18)Patients ADAb − (n=87)p Value
Biologic at baseline, no. (%):
 Infliximab9 (37.5)14 (58.3)
 Etanercept0 (0)48 (100)
 Adalimumab9 (27.3)24 (72.7)
Therapeutic response, no. (%):4 (22.2)54 (62.1)0.003
Low disease activity, no. (%):1 (5.6)30 (34.5)0.02
  • Values shown are n (%). Therapeutic response was assessed every 3 months and defined as an improvement DAS28>1.2 and DAS28≤3.2, improvement DAS28>1.2 and DAS28>3.2 or improvement 0.6>DAS28≤1.2 and DAS28≤5.1 (EULAR good and moderate response). Low disease activity was defined as a present DAS28≤3.2.

  • p Values were obtained from χ2 tests.

  • ADAb + −, antidrug antibodies positive; ADAb− −, antidrug antibodies negative.